International Tax for Life Sciences, Healthcare & Pharmaceuticals
- Extax Oceania
- 17 hours ago
- 2 min read
Direct answer: life-sciences tax must follow where research, clinical, regulatory, manufacturing and commercial functions are performed and controlled. Legal ownership of a patent or product does not settle who created value, bears development risk or should earn the return from licensing and commercialisation.
Key cross-border tax risks
R&D, clinical, regulatory and product-development functions
IP ownership, licensing and economically significant control
Manufacturing, quality and distribution transfer pricing
Healthcare professional, researcher and contractor presence
Funding, grants, investors and cross-border equity
Licensing, acquisitions, milestones and exits
What changes the tax result
Who controls the research and development programme?
Scientific strategy, budgets, study design, regulatory decisions and go-or-stop authority should match the entity attributed with development risk and IP returns.
Where are clinical and regulatory functions performed?
Trial sites, investigators, regulatory teams and local representatives can create taxable presence, service charges and payroll obligations.
How are manufacturing and commercial functions divided?
Contract manufacturers, quality control, supply risk, distribution, medical affairs and sales should receive returns consistent with their functions and risks.
Has a founder or scientific leader moved overseas?
Relocation can shift company control, IP decision-making, employment and founder-equity consequences even where laboratories and legal ownership remain in Australia.
Worked scenario
An Australian biotech founder relocates to Boston to lead clinical development and fundraising. Australian researchers continue discovery work, a US company employs the clinical team and a European manufacturer is engaged for production.
The review must coordinate founder residence, company control, R&D and clinical functions, IP ownership, intercompany funding and services, manufacturing risk, employee equity and future licensing or exit proceeds.
Evidence to assemble
R&D, clinical and regulatory plans and approvals
IP, licence, collaboration and funding agreements
Manufacturing, quality and distribution contracts
Researcher, clinician, employee and contractor records
Founder residence, equity and management evidence
Grant, investor, milestone and transaction documents
How Extax helps
Extax coordinates founder and company residence, R&D and IP structures, transfer pricing, clinical and service arrangements, manufacturing, funding, acquisitions, licensing and exits around the actual scientific and commercial model.
Extax Oceania
Ex Big 4 | International Tax
Published and technically updated 28 July 2026.
This page provides general information only. Clinical, pharmaceutical, healthcare, regulatory, IP and local tax requirements must be confirmed with appropriately qualified advisers.
Comments